Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts

High engraftment rates are critical to any patient-derived xenograft (PDX) program and the loss of PDX models due to the development of lymphoproliferative tumors (LTs) is costly and inefficient. We hypothesized that routine injection of rituximab, an anti-CD20 antibody, at the time of implantation...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiting, Jennifer L., Hernandez, Matthew C., Yang, Lin, Bergquist, John R., Ivanics, Tommy, Graham, Rondell P., Truty, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459856/
https://www.ncbi.nlm.nih.gov/pubmed/30976061
http://dx.doi.org/10.1038/s41598-019-42470-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459856/
https://www.ncbi.nlm.nih.gov/pubmed/30976061
http://dx.doi.org/10.1038/s41598-019-42470-w

Ejemplares similares